Page 1 of 63
“HESI PHARMACOLOGY “ LATEST 2025 EXAM 1
UPDATED 2025 – 2026 SOLVED QUESTIONS &
ANSWERS VERIFIED 100% GRADED A+ (LATEST
VERSION)
2025 HESI RN Pharmacology Exam Test Bank EXAM QUESTIONS WITH COMPLETE
SOLUTION) (MULTIPLE CHOICES) (A+ GRADED 100% VERIFIED) LATEST VERSION
2025
The use of genetic information to guide the choice of drug therapy is called:
a- Pharmacoepidemiology
b- Pharmacogenetics
c- Biotechnology
d- Pharmacogenomics
D: Pharmacogenomics
The magnitude of the receptors to a drug is related to the:
a- Total number of receptors for the drug
b- Number of receptors occupied by the drug
c- Number of vacant receptors in the tissue
d- Number of phosphorylated receptors in the tissue
B: Number of receptors occupied by the drug
In epidermal growth factor kinase cascade, MAP (mitogen-activated protein)
kinase acts to phosphorylate:
a- DNA
b- Transcription factors
c- Cyclic AMP
d- Ion channels
, Page 2 of 63
B: Transcription Factors
4) In Australia, drugs and poisons are regulated by placing them in:
a- Jurisdictions
b- Classifications
c- Regulations
d- Schedules
D: Schedules
The statement that best describes a partial agonist is:
a- Partial agonists produce the same maximal response as the endogenous
ligand
b- Partial agonists produce less than the maximal response even when all the
receptors are occupied
c- Partial agonists are always less potent than full agonists
d- Partial agonists bind to the receptor and block the action of the endogenous
ligand without producing any effects of their own
B: Partial agonists produce less than the maximal response even
6) Drug A has a hepatic clearance (CLH) of 60L/h. Assuming the liver blood
flow is 90L/h (QH), the hepatic extraction ratio (EH) of Drug A is: CLH = EH X
QH
a- 0.33
b- 0.67
c- 0.54
d- 1.50
B: 0.67
7) Drug A has a volume of distribution (Vd) of 30L and the target plasma drug
concentration (CP) is 12mg/L. The loading dose required is: Vd = Dose/CP
a- 360mg
b- 2.5mg
c- 25mg
d- 400mg
A: 360mg
, Page 3 of 63
Transdermal drug administration:
a- Is most suitable for highly polar drugs
b- Is not subject to first-pass metabolism
c- Provides rapid and complete absorption
d- Is most suitable for unconscious persons
B: Is not subject to first-pass metabolism
In first-order drug elimination:
a- Drug half-life is directly proportional to drug concentration
b- The rate of elimination is directly proportional to drug concentration
c- Drug clearance is directly proportional to plasma drug concentration
d- The rate of elimination is constant
B: The rate of elimination is directly proportional to drug concentration
Drug A has a systemic clearance of 20L/h and a volume of distribution of 400L.
The half-life of the drug is:
a- 20.86h
b- 0.05h
c- 13.86h
d- 0.03h
C: 13.86h
Half-life = 0.693 X 400L/20L/h
Which substance blocks ion channels of N-methyl-D-aspartate (NMDA)
receptors for excitatory amino acids?
a- Ketamine
b- Cyclosporine
c- Verapamil
d- Cyclothiazide
A: Ketamine
Functions associated with noradrenergic pathways in the central nervous
system include:
a- Feeding behaviour
b- Induction of sleep
, Page 4 of 63
c- Control of mood
d- Release of hormones
C: Control of mood
The use of selegiline in Parkinson's disease is based on its ability to: The
enzyme that breaks down dopamine to make dopamine last longer
a- Selectively inhibit type B monoamine oxidase
b- Increase dopamine
c- Inhibit peripheral degradation of levodopa
d- Protect dopamine from intra-neuronal degradation
A: Selectively inhibit type B monoamine oxidase
Drug therapy for Parkinson's disease is focused on:
a- Increasing dopamine levels or stimulating acetylcholine effects
b- Increasing dopamine levels or blocking acetylcholine effects
c- Decreasing dopamine levels or stimulating acetylcholine effects
d- Decreasing dopamine levels or blocking acetylcholine effects
B: Increasing dopamine levels or blocking acetylcholine effects
The mechanism of action of diazepam and other benzodiazepines is:
a- Facilitating the action of GABA on GABAA receptors, thereby enhancing
chloride influx into the neuronal cell
b- Inhibiting the action of GABA on GABAA receptors, thereby inhibiting
chloride influx into the neuronal cell
c- Facilitating the action of GABA on GABAA receptors, thereby inhibiting
chloride influx into the neuronal cell
d- Facilitating the action of GABA on GABAB receptors, thereby enhancing
chloride influx into the neuronal cell
A: Facilitating the action of GABA on GABAA receptors, thereby enhancing chloride
influx into the neuronal cell
“HESI PHARMACOLOGY “ LATEST 2025 EXAM 1
UPDATED 2025 – 2026 SOLVED QUESTIONS &
ANSWERS VERIFIED 100% GRADED A+ (LATEST
VERSION)
2025 HESI RN Pharmacology Exam Test Bank EXAM QUESTIONS WITH COMPLETE
SOLUTION) (MULTIPLE CHOICES) (A+ GRADED 100% VERIFIED) LATEST VERSION
2025
The use of genetic information to guide the choice of drug therapy is called:
a- Pharmacoepidemiology
b- Pharmacogenetics
c- Biotechnology
d- Pharmacogenomics
D: Pharmacogenomics
The magnitude of the receptors to a drug is related to the:
a- Total number of receptors for the drug
b- Number of receptors occupied by the drug
c- Number of vacant receptors in the tissue
d- Number of phosphorylated receptors in the tissue
B: Number of receptors occupied by the drug
In epidermal growth factor kinase cascade, MAP (mitogen-activated protein)
kinase acts to phosphorylate:
a- DNA
b- Transcription factors
c- Cyclic AMP
d- Ion channels
, Page 2 of 63
B: Transcription Factors
4) In Australia, drugs and poisons are regulated by placing them in:
a- Jurisdictions
b- Classifications
c- Regulations
d- Schedules
D: Schedules
The statement that best describes a partial agonist is:
a- Partial agonists produce the same maximal response as the endogenous
ligand
b- Partial agonists produce less than the maximal response even when all the
receptors are occupied
c- Partial agonists are always less potent than full agonists
d- Partial agonists bind to the receptor and block the action of the endogenous
ligand without producing any effects of their own
B: Partial agonists produce less than the maximal response even
6) Drug A has a hepatic clearance (CLH) of 60L/h. Assuming the liver blood
flow is 90L/h (QH), the hepatic extraction ratio (EH) of Drug A is: CLH = EH X
QH
a- 0.33
b- 0.67
c- 0.54
d- 1.50
B: 0.67
7) Drug A has a volume of distribution (Vd) of 30L and the target plasma drug
concentration (CP) is 12mg/L. The loading dose required is: Vd = Dose/CP
a- 360mg
b- 2.5mg
c- 25mg
d- 400mg
A: 360mg
, Page 3 of 63
Transdermal drug administration:
a- Is most suitable for highly polar drugs
b- Is not subject to first-pass metabolism
c- Provides rapid and complete absorption
d- Is most suitable for unconscious persons
B: Is not subject to first-pass metabolism
In first-order drug elimination:
a- Drug half-life is directly proportional to drug concentration
b- The rate of elimination is directly proportional to drug concentration
c- Drug clearance is directly proportional to plasma drug concentration
d- The rate of elimination is constant
B: The rate of elimination is directly proportional to drug concentration
Drug A has a systemic clearance of 20L/h and a volume of distribution of 400L.
The half-life of the drug is:
a- 20.86h
b- 0.05h
c- 13.86h
d- 0.03h
C: 13.86h
Half-life = 0.693 X 400L/20L/h
Which substance blocks ion channels of N-methyl-D-aspartate (NMDA)
receptors for excitatory amino acids?
a- Ketamine
b- Cyclosporine
c- Verapamil
d- Cyclothiazide
A: Ketamine
Functions associated with noradrenergic pathways in the central nervous
system include:
a- Feeding behaviour
b- Induction of sleep
, Page 4 of 63
c- Control of mood
d- Release of hormones
C: Control of mood
The use of selegiline in Parkinson's disease is based on its ability to: The
enzyme that breaks down dopamine to make dopamine last longer
a- Selectively inhibit type B monoamine oxidase
b- Increase dopamine
c- Inhibit peripheral degradation of levodopa
d- Protect dopamine from intra-neuronal degradation
A: Selectively inhibit type B monoamine oxidase
Drug therapy for Parkinson's disease is focused on:
a- Increasing dopamine levels or stimulating acetylcholine effects
b- Increasing dopamine levels or blocking acetylcholine effects
c- Decreasing dopamine levels or stimulating acetylcholine effects
d- Decreasing dopamine levels or blocking acetylcholine effects
B: Increasing dopamine levels or blocking acetylcholine effects
The mechanism of action of diazepam and other benzodiazepines is:
a- Facilitating the action of GABA on GABAA receptors, thereby enhancing
chloride influx into the neuronal cell
b- Inhibiting the action of GABA on GABAA receptors, thereby inhibiting
chloride influx into the neuronal cell
c- Facilitating the action of GABA on GABAA receptors, thereby inhibiting
chloride influx into the neuronal cell
d- Facilitating the action of GABA on GABAB receptors, thereby enhancing
chloride influx into the neuronal cell
A: Facilitating the action of GABA on GABAA receptors, thereby enhancing chloride
influx into the neuronal cell
